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Introduction: RosaieDorfman Disease (RDD), also known as Sinus Histiocytosis with Massive
Lymphadenopathy (SHML), is a rare monocyte/macrophage proliferative disorder of varied bio-
logical behavior. Although cutaneous and lymph node involvement are relatively well-
described, intrathoracic manifestations of RDD have only occasionally been reported.
Methods: We conducted a retrospective computer-assisted search of the Mayo Clinic record
from 1976 to 2005 for patients with histopathologic evidence of RDD on organ biopsy. Clinical
characteristics were abstracted from charts and thoracic manifestations recorded. Survival
was estimated using the national social security database.
Results: A total of 21 patients were diagnosed with RDD over a period of 30 years; 9 had intra-
thoracic manifestations (43%). Main pulmonary symptoms included dyspnea and cough. Age at
the time of diagnosis, gender, race, smoking history, mortality and time of survival after diag-
nosis were no different between RDD patients with and without intrathoracic manifestations.
The most common radiographic thoracic manifestation was mediastinal lymphadenopathy
(6 patients). Cystic change, interstitial lung disease, and airway disease were radiographically
evident in 4 patients. Seven patients were treated at some point in the course of their disease,
most commonly with oral corticosteroids. At the time of last follow-up 87% were alive, with
a median (IQR) time interval since diagnosis of 8 years (4e9.7).
Conclusions: Intrathoracic manifestations of RDD are relatively common and include medias-
tinal lymphadenopathy, airway disease, pleural effusion, cystic and interstitial lung disease.
Although limited in size, this series suggests the prognosis of patients with RDD and intratho-
racic manifestations is relatively good.
ª 2010 Elsevier Ltd. All rights reserved.7 284 5398.
ayo.edu (R. Vassallo).
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In 1969, Rosai and Dorfman described a series of individuals
with a non-malignant lymphohistiocytic proliferative
condition predominantly involving lymph nodes and clini-
cally resulting in painless lymphadenopathy.1 In a later
publication, 30 additional cases of this unique condition
were described, resulting in the establishment of sinus
histiocytosis with massive lymphadenopathy (SHML) or
RosaieDorfman disease (RDD), as a clinicopathologic
entity.2 Other lymphatic groups, such as mediastinal, axil-
lary and inguinal lymph nodes can also be involved, and in
approximately 25e40% of cases, extranodal sites are
affected.3e5 Extranodal involvement is often responsible
for the more clinically significant manifestations of the
disease.6 Although sporadic cases of thoracic RDD have
been reported in the literature,3,7e9 the clinical and
radiological characteristics, progression, therapy and
survival of RDD patients with predominantly intrathoracic
involvement have not been well defined. In this retro-
spective study, the clinical and radiological findings, as well
as therapy and outcomes of a cohort of patients with RDD
and intrathoracic manifestations are described.
Methods
The Mayo Clinic Institutional Review Board approved the
study protocol. A retrospective computer-assisted search of
the Mayo Clinic records from 1976 to 2005 for patients with
histopathologic evidence of RDD on organ biopsy was per-
formed. Individuals with an unequivocal histopathological
diagnosis of RDD were included. Clinical characteristics
were abstracted from paper and electronic medical records
and intrathoracic manifestations recorded. All radiological
images were reviewed by three of the authors (RCC, RV and
JMG). Survival was assessed utilizing the national social
security database. Clinical characteristics were compared
between RDD subjects with intrathoracic manifestations
and RDD subjects without intrathoracic manifestations.
Statistical analysis: All continuous data are summarized
as medians (interquartile range, IQR). Categorical data are
summarized as percentages. Difference in medians
between groups was tested with the Wilcoxon sum rank
test. Differences in proportions were compared utilizing
the chi-squared test or the Fisher exact test as appropriate.
Death was determined from the state and national death
index. JMP 8.0 software was utilized for analysis of the
data. For all statistical tests, a 2-tailed P value of <0.05
was considered statistically significant.
Results
A total of 21 patients were diagnosed with RDD over
a period of 30 years at our institution; 9 (43%) had evidence
of intrathoracic RDD. Table 1 presents the comparison of
the clinical characteristics between RDD subjects with
intrathoracic manifestations and RDD subjects without.
There were no significant differences between the two
groups in age at the time of diagnosis, gender, race,
smoking history, mortality or time of survival after diagnosis
(Table 1). Clinical and radiographic characteristics ofpatients with intrathoracic RDD are summarized in Table 2.
In patients with intrathoracic RDD manifestations, the most
common respiratory symptoms included dyspnea in 8
patients and cough in 5. Only two smokers were identified.
Pulmonary function tests were only available for 3 patients,
one of which was normal; the other 2 studies demonstrated
moderate restrictive physiology and low diffusing capacity
of the lung for carbon monoxide (DLCO) in 1 patient, and
mild obstructive physiology with normal DLCO in the last
patient.
The most common intrathoracic manifestation of RDD
was mediastinal lymphadenopathy in 6 patients (66%). The
most common extrathoracic manifestation among patients
with intrathoracic RDD was cervical lymphadenopathy in 6
patients (66%). Four patients (44%) presented to clinical
attention primarily because of respiratory tract disease;
the main imaging findings in these 4 cases were cystic lung
disease, airway disease (air trapping and bronchiectasis),
pleural effusion with mediastinal adenopathy (Fig. 1), and
interstitial lung infiltrates in two patients (Fig. 2). Fig. 2
illustrates the radiological findings in one of the patients
with interstitial pulmonary infiltrates. The diagnosis of RDD
with interstitial lung infiltrates was established in two
patients following identification of typical features of RDD
on surgical lung biopsy (Fig. 3). Seven patients received
pharmacotherapy during the course of their disease, most
commonly with oral corticosteroids. The 2 patients not
treated with corticosteroids remained stable during the
follow up period. The majority of patients demonstrated
subjective clinical improvement after therapy with steroids
(6 patients), and one patient (patient #9) experienced
a decline in a one-year follow-up pulmonary function
testing showing a severe restrictive pattern. This patient
developed worsening oxygenation and was evaluated for
lung transplantation at another academic institution. At the
time of last follow-up, all patients except one were still
alive, for a median (IQR) survival of 8 years (4e9.7) after
diagnosis. All three fatalities in the cohort were non-RDD
related (cardiovascular events).
Discussion
In this retrospective cohort of 21 adult patients with biopsy-
proven RDD identified over a period of 30 years at a tertiary
care institution, we report that a significant proportion of
patients develop intrathoracic involvement. In addition, we
have identified mediastinal lymphadenopathy as the most
common intrathoracic manifestation of RDD. The current
study also reports the occurrence of RDD as an interstitial
pulmonary process with radiographic features that are
similar to those reported in idiopathic interstitial pneu-
monias. The disease follows a relatively benign course in
most patients and the occurrence of intrathoracic involve-
ment with RDD does not seem to portend a worse prognosis
compared to other patients without thoracic involvement.
RDD is a disorder characterized by non-malignant
proliferation of distinctive histiocytic/phagocytic cells
primarily within lymph node sinuses and lymphatics in
extranodal sites.3,10 The histiocytic disorders are classified
according to the presumed cell of origin. Langerhans cell
Histiocytosis (LCH) and RDD are both disorders of
varied biological behavior originating from abnormally
Table 1 Clinical characteristics of RosaieDorfman disease patients with and without intrathoracic manifestations.
Intrathoracic
manifestations N Z 9
No intrathoracic
manifestations N Z 12
P value
Age at diagnosis (years) median, IQR 45 (23e50) 53 (35e68) 0.24
Female gender, N (%) 5 (56) 8 (67) 0.67
Caucasians, N (%) 8 (89) 9 (75) 0.60
Prior smoking history, N (%) 2 (22) 1 (8.3) 0.55
Mortality, N (%) 1 (11) 2 (17) 0.99
Time alive after diagnosis (years), median (IQR) 8 (4e9.7) 7.9 (4.9e14.8) 0.77
N Z Number, IQR: Interquartile range.
1346 R. Cartin-Ceba et al.proliferating histiocytic cells; however, LCH and RDD are
clinically distinct entities. While LCH is a dendritic cell
proliferative disorder, RDD is a monocyte/macrophage
proliferative disease.11 RDD most commonly affects young
adults in the first or second decade, although it may
present at any age group, as observed in our study. Our
relatively older cohort is likely due to referral bias because
our institution receives a large referred adult population.
There is no particular gender predilection in our study
which is similar to previous reports.3 Our cohort was
predominantly Caucasian, which differs from the largest
published series which reported a slight predominance in
African Americans.3 Unlike certain proliferative histiocytic
disorders like pulmonary LCH, the prevalence of cigarette
smoking was very low in the current series, suggesting
a lack of association between smoking and RDD.
Themostcommonpresenting symptom in thevastmajority
of patients is painless cervical lymphadenopathy.1e3,12
Cutaneous manifestations are reported to occur in about
10% of patients, and generally consist of asymptomatic
xanthoma-like, yellowish or reddish-brown papules, nodules
and plaques which may ulcerate.3,10 Respiratory tract
involvement has been described in less than 3% of the cases in
a large review of 423 registry patients and carries a worse
prognosis.3 Pulmonary parenchymal involvement has also
been reported in a case report.13 In the current series, we
describe intrathoracic manifestations in 9 out of 21 RDD
patients; in 5 patients the intrathoracic involvement was
determined based on the presence of mediastinal lymph-
adenopathy which could not be explained by alternative
etiologies, and was associated with confirmatory biopsies of
other sites, predominantly enlarged cervical nodes and skin.
When considering only individualswith lower respiratory tract
involvement, 4 out of 21 patientswere affected, representing
a higher percentage and also a better prognosis than previ-
ously described. Case reports have been published on primary
central airway involvement,9 and pleural involvement.7 In the
current series, one patient had a pleural effusion. However,
no endotracheal or endobronchial diseasewas documented in
our study. In the two patients inwhom interstitial diseasewas
observed, the radiographic pattern of involvement showed
the presence of an interstitial infiltrate in both lungs, greater
in the periphery and in the bases. Cystic change and honey-
combingwereminimal or absent. Prior to surgical lung biopsy,
the provisional diagnosis based on imaging findings was
consistent with non-specific interstitial pneumonia in one of
these cases (see Fig. 2). The 18F-Fluorodeoxyglucose (18FDG)
positron emission tomography (PET-CT) scan maydemonstrate pathologic uptake in involved organs, and may
beuseful in documented theextent of disease inpatientswith
RDD, as recently reported.5,14
Laboratory testing shows no specific abnormalities in
RDD. The diagnosis is made on the basis of characteristic
clinical features (particularly the presence of painless
adenopathy with or without skin or other manifestations) in
combination with characteristic histologic findings in tissue
biopsy specimens. There are two cardinal features on
histology.15 The first is the presence of emperipolesis which
represents histiocytic phagocytosis of intact lymphocytes,
plasma cells, and cellular debris as illustrated in Fig. 3. The
second is a characteristic pattern of cell surface receptor
expression: positive for S100 protein, CD14, CD68 (macro-
phage markers), positive for CD11c (early dendritic cell
marker), but negative for CD1a (positive on Langerhans-
type of dendritic cells) and MHC-2 (generally positive on
dendritic cells).8 Thus the cell of origin of RDD is postulated
to be a monocyte-derived cell that is on its way to macro-
phage differentiation and at the same time has some
markers of early dendritic cell phenotype. The background
often shows mixed inflammatory infiltrates rich in plasma
cells as illustrated in Fig. 3. The differential diagnosis
includes atypical chronic infections (mycobacterial or
fungal), certain indolent low-grade lymphomas, immuno-
globulinG4 (IgG4)-related interstitial lung disease,
Erdheim-Chester disease, and Langerhans cell Histiocy-
tosis.1,2,8,10,16,17 All our patients had biopsy-proven disease
mainly from lymphatic nodes; however, three patients were
diagnosed based on lung biopsies.
RDD, though a benign disorder, can sometimes behave in
an aggressive manner, leading to significant morbidity and
mortality. Approximately 50% of patients do not require
therapy and spontaneous remissions have been described to
occur.18 Our study showed only few deaths with non-RDD
related fatalities. Moreover, the median survival was
greater than 5 years after diagnosis, irrespective of extra-
nodal involvement. For patients with progressive or symp-
tomatic presentation, or patients with prominent cosmetic
problems due to cutaneous disease, corticosteroids
have been widely suggested but their efficacy is
unclear.2,12,15,18e21 Most of the patients described in this
study were treated with corticosteroids with adequate
response. Surgery, radiation therapy and/or chemotherapy
(vinca alkaloids, cladribine, rituximab, 6-mercaptopurine
and oral methotrexate) have been considered in patients
not adequately controlled with steroid treatment.5,12,18,22
There are a few case reports describing the use of alpha-
Table 2 Clinical, radiological and therapeutic characteristics of patients with RDD and intrathoracic manifestations.
Gender Age
(years)a
Survival Site of
biopsy
Respiratory
symptoms
Non-pulmonary
manifestations
Smoking
history
PFT CT findings Treatment Outcome
1 Female 2 Alive Cervical
lymph node
- Dyspnea and
cough
- Cervical
lymphadenopathy
No Not performed - Mediastinal
lymphadenopathy with
mild airway extrinsic
compression
- Steroids
- Methotrexate
- 6-Mercaptopurine
- Vinblastine
Improved
2 Female 45 Alive Cervical
lymph node
- Dyspnea
- Cough
- Cervical
lymphadenopathy
No Not available Not available - Chlorambucil
- Steroids
Improved
3 Male 51 Alive Cervical
lymph node
- Dyspnea - Cervical and
abdominal
lymphadenopathy
- Scotomas
Active
15 pack/year
Normal - Mediastinal
lymphadenopathy
- Air trapping
- Steroids Improved
4 Female 50 Alive Skin - Dyspnea
- Sore throat
- Hoarseness
- Skin changes
- Uveitis
- Cervical
lymphadenopathy
No Mild obstruction
normal DLCO
- Pulmonary cysts lower
lung predominant
- Bronchiectasis
- No Not available
5 Male 46 Dead Mediastinal
lymph node
- Dyspnea - Splenomegaly Former
10 pack/year
Not available - Pleural effusion
- Mediastinal
lymphadenopathy
- Steroids Improved
6 Female 41 Alive Lung - Cough
- Wheezing
- None No Not available - Mediastinal
lymphadenopathy
- Peribronchial lymph
node enlargement
- No Stable
7 Female 21 Alive Cervical
lymph node
- Dyspnea
- Cough
- Cervical
lymphadenopathy
- Nasal congestion
No Not available - Mediastinal
lymphadenopathy
- Steroids
- Interferon-alpha
Improved
8 Male 73 Alive Lung - Dyspnea - Cervical and
abdominal
lymphadenopathy
- Lower extremity
edema
No Not available - Bilateral
interstitial infiltrates
- Hilar and mediastinal
lymphadenopathy
- Steroids Improved
9 Male 26 Alive Lung - Dyspnea
- Cough
- None No Moderate
Restriction
DLCO 33%
- Bilateral interstitial
infiltrates
- Steroids Worsening
PFTs: Pulmonary function test, RDD: RosaieDorfman Disease, CT: Computed tomography, DLCO: diffusing capacity of the lung for carbon monoxide.
a Age at time of diagnosis.
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Figure 1 Contrast-enhanced CT of the chest showing left
sided pleural effusion and the presence of mediastinal
lymphadenopathy in a 46 year-old patient with RDD (patient #5
in Table 2). Diagnosis of RDD was established by mediastinal
lymph node biopsy.
1348 R. Cartin-Ceba et al.interferon.18,23 One patient in the current series was
treated with interferon-alpha. Unfortunately, that patient
was lost to follow up.
We acknowledge several limitations in the current study.
First, our study has a retrospective observational designFigure 3 A. Histopathologic findings on surgical lung biopsy
(patient #8 in Table 2) demonstrating interstitial thickening
due to abnormal histiocytic collections and associated mixed
inflammatory infiltrates (hematoxylin eosin staining, 400
original magnification). Arrows point to histiocytic cells
engulfing leukocytes (emperipolesis e see insert). B. Histo-
pathologic findings on surgical lung biopsy of a 26 year-old
patient with RDD whose CT is shown in Fig. 2. Histiocytes
contain intracytoplasmic leukocytes (emperipolesis) (arrows)
and are accompanied by mixed inflammatory infiltrates
including many plasma cells (hematoxylin and eosin staining,
400 original magnification). Abnormal histiocytes are positive
for S100 staining (inset; anti-S100 immunohistochemical
staining, 400 original magnification).
Figure 2 Representative non-enhanced high resolution CT
images from the upper (panel A) and lower chest (panel B) in
a 26 year-old patient with surgical lung biopsy-proven RDD
show bilateral, subpleural reticular opacities, bilateral scat-
tered areas of ground glass attenuation, and mild traction
bronchiectasis in the bases. A few tiny cystic lesions are
present in the upper lung fields, but no honeycombing was
present.with its inherent biases. Complete medical records and
follow up were not widely available for all patients. Also,
the findings from the current study may reflect regional
referral biases particular to our institution and may be
difficult to generalize.
Conclusions
Intrathoracic manifestations of RDD are common and
include mediastinal lymphadenopathy, airway disease,
pleural effusion, cystic and interstitial lung disease.
Although limited in size, this series suggests the prognosis
of patients with RDD and intrathoracic manifestations is
relatively good.
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